

Human Papillomavirus (HPV) Vaccine Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Human Papillomavirus (HPV) Vaccine Market Report and Forecast 2024-2032??

The human papillomavirus (HPV) vaccine market attained a value of nearly USD 5.22 billion in 2023. The market is estimated to grow at a CAGR of 11.60% during the period 2024-2032, reaching about USD 14 billion by 2032. This growth is driven by increased awareness of HPV-related diseases and the effectiveness of vaccination programmes, alongside advancements in vaccine technology and government initiatives.

Human Papillomavirus (HPV) Vaccine Market- Analysis

The human papillomavirus vaccine market is witnessing substantial growth due to increased awareness of human papillomavirus-related cancers and the proven effectiveness of vaccines in preventing these diseases. HPV vaccines are crucial in reducing the incidence of cervical and other cancers, making them essential components of public health strategies worldwide. This heightened awareness and the vaccines' role in cancer prevention are driving significant market expansion and adoption, positioning human papillomavirus vaccines as vital tools in health initiatives.

Market Driver

Technological Advancements: Continuous innovation in vaccine technology has significantly enhanced the efficacy and safety of HPV vaccines. These advancements are driving market growth as healthcare providers seek more reliable and effective

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

preventive solutions. Enhanced delivery mechanisms, improved formulations, and broader protection against multiple HPV strains are making these vaccines more appealing. Additionally, advancements in cold chain logistics are improving vaccine distribution and storage, ensuring vaccines reach remote and underserved regions, thus broadening market reach.

Government Initiatives: Governments around the world are actively implementing vaccination programmes to combat HPV-related diseases. These initiatives significantly boost market demand by increasing vaccine accessibility and public awareness. Government-backed campaigns, subsidies, and the inclusion of HPV vaccines in national immunisation schedules are crucial in driving vaccination rates. These efforts not only enhance public health outcomes but also create a stable demand for HPV vaccines, encouraging manufacturers to invest in research and production.

Rising Awareness: Increased awareness about the risks associated with HPV and the benefits of vaccination is propelling market growth. Educational campaigns, media coverage, and advocacy by health organisations are pivotal in encouraging vaccine uptake. As more people become informed about HPV's link to various cancers and the preventive power of vaccines, the demand for HPV vaccinations rises. This growing awareness is critical in overcoming vaccine hesitancy and boosting overall vaccination rates.

Preventive Healthcare Demand: The growing emphasis on preventive healthcare is driving demand for HPV vaccines. Preventive measures are increasingly recognised for their cost-effectiveness in reducing long-term healthcare expenses. By preventing HPV-related diseases, vaccines help reduce the burden on healthcare systems and improve population health outcomes. This trend towards preventive care is fostering a proactive approach among individuals and healthcare providers, thereby fuelling market growth.

Market Challenges

High Costs: The high cost of HPV vaccines can limit accessibility, especially in low-income regions. This financial barrier is a significant challenge for widespread adoption. Despite subsidies and support programmes, the initial expense of the vaccine can be prohibitive for many. Efforts to reduce costs through bulk purchasing, manufacturing efficiencies, and financial assistance programmes are crucial to making vaccines more affordable and accessible.

Vaccine Hesitancy: Public scepticism and misinformation about vaccines pose significant challenges to market growth. Addressing these concerns through education, transparent communication, and community engagement is essential. Overcoming vaccine hesitancy requires a multifaceted approach involving healthcare providers, public health organisations, and policymakers to build trust and confidence in the safety and efficacy of HPV vaccines.

Supply Chain Issues: Ensuring a consistent supply of vaccines can be challenging, particularly in remote or underserved areas. Supply chain disruptions can impact vaccine availability and distribution. Effective supply chain management, improved logistics, and strategic partnerships are necessary to maintain a steady flow of vaccines. Addressing these challenges is vital to ensure that vaccines reach all regions, especially during times of increased demand or logistical disruptions.

Future Opportunities

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Emerging Markets: Expanding into emerging markets with improving healthcare infrastructure presents substantial growth opportunities. These regions offer untapped potential for increasing vaccine coverage. As healthcare systems in these markets develop, the demand for preventive healthcare, including HPV vaccines, is expected to rise. Strategic investments and partnerships in these regions can drive market expansion and improve public health outcomes.

Innovative Delivery Methods: Developing new vaccine delivery methods, such as needle-free options, can enhance vaccine uptake. These innovations can improve user experience, reduce fear of injections, and increase accessibility. Needle-free delivery systems and other novel administration techniques can make vaccination more appealing and convenient, especially for those with needle phobia or in settings where traditional injection methods are challenging.

Collaborations and Partnerships: Strategic partnerships between vaccine manufacturers, healthcare providers, and government agencies can drive market expansion. Collaborations can facilitate research, development, and distribution efforts, ensuring broader vaccine access. These partnerships can also support public health campaigns and educational initiatives, further promoting vaccination and addressing barriers to uptake.

Expanded Indications: Research into additional indications for HPV vaccines, such as protection against other cancers and diseases, can broaden the market scope. This expansion can drive further growth and adoption by offering more comprehensive protection. Ongoing clinical trials and studies exploring new uses for HPV vaccines can lead to enhanced product offerings, attracting a wider audience and increasing market penetration.

Market Trends

Increase in Vaccination Programmes: The expansion of vaccination programmes is a significant trend. These programmes aim to increase coverage and reduce the incidence of HPV-related diseases, driving market growth. National and international health organisations are prioritising HPV vaccination, resulting in higher immunisation rates and enhanced public health outcomes. This trend is supported by increased funding and policy initiatives that promote vaccine accessibility.

Technological Integration: Integrating advanced technologies such as AI, big data, and blockchain in vaccine research and distribution is enhancing efficiency. These technologies improve targeting, monitoring, and logistical management of vaccination efforts. AI can optimise vaccine distribution routes, while big data analytics provide insights into vaccination coverage and efficacy. Blockchain ensures transparency and security in the supply chain, building trust in vaccine quality.

Growing Focus on Male Vaccination: Increasing awareness of HPV-related diseases in males is driving vaccination efforts. Expanding vaccination to include boys and men is a growing trend that supports market growth. HPV vaccination programmes targeting males help reduce the overall transmission of the virus and prevent related cancers in men, contributing to broader public health benefits and market expansion.

Public-Private Partnerships: Collaborations between governments and private companies are becoming more common. These partnerships enhance vaccine research, production, and distribution, benefiting overall market growth. Public-private partnerships

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

facilitate resource sharing, accelerate innovation, and improve the reach of vaccination programmes. By leveraging the strengths of both sectors, these collaborations can address challenges and drive market progress.

Human Papillomavirus (HPV) Vaccine Market Segmentation

Breakup by Type

Bivalent

Polyvalent

The HPV vaccine market is segmented by type into bivalent and polyvalent vaccines. Bivalent vaccines target specific human papillomavirus strains, while polyvalent vaccines cover multiple strains. Both segments are crucial for market growth, addressing diverse prevention needs. Technological advancements and rising awareness are boosting demand for these vaccines, with polyvalent vaccines gaining popularity for their broader protection. The forecast period will see these segments driving market growth through improved efficacy and expanded immunisation programmes.

Market Breakup by Indication

Genital Warts

HPV Associated Cancer

The market is segmented by indication into genital warts and human papillomavirus-associated cancer. Vaccines targeting genital warts and human papillomavirus-associated cancers are essential for comprehensive human papillomavirus prevention. Increased awareness and vaccination programmes drive demand in both segments. HPV-associated cancer vaccines are particularly critical, given the rising incidence of cervical and other cancers. Future growth will be driven by expanded vaccination efforts and new indications, enhancing overall market expansion.

Market Breakup by Route of Administration

Intravenous

Intramuscular

Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The HPV vaccine market is segmented by route of administration into intravenous, intramuscular, and others. Intramuscular administration is the most common and effective route, driving most of the market demand. Intravenous and other routes provide alternatives for specific medical needs. Advancements in vaccine delivery methods and increasing vaccination rates support market growth, with intramuscular administration leading due to its widespread acceptance and efficacy.

Market Breakup by Distribution Channel

Hospital and Retail Pharmacies

Government Suppliers

Others

The market is segmented by distribution channel into hospital and retail pharmacies, government suppliers, and others. Hospital and retail pharmacies dominate the distribution of human papillomavirus vaccines, driven by accessibility and trust. Government suppliers play a crucial role in mass vaccination programmes, enhancing public health outcomes. Increasing collaboration between public and private sectors, along with expanded distribution networks, will drive market growth across these channels.

Market Breakup by Region

United States

EU-4 and the United Kingdom

Germany

France

Italy

Spain

United Kingdom

Japan

India

The HPV vaccine market is segmented by region into the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. The United States and Europe lead the market due to established healthcare systems and high vaccination rates. Japan and India are emerging markets with significant growth potential, driven by increasing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

awareness and government initiatives. These regions will drive market expansion through improved healthcare infrastructure and expanded vaccination efforts.

Human Papillomavirus (HPV) Vaccine Market Competitive Landscape

The human papillomavirus (HPV) vaccine market features several key players actively shaping the competitive landscape. Notable companies include Merck & Co., Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Bharat Biotech International Limited (BBIL), Inovio Pharmaceuticals Inc., Sanofi SA, Beijing Wantai Biolog Pha Ent Co Ltd, and Walvax Biotechnology Co., Ltd. These companies engage in activities such as mergers and acquisitions, research initiatives, product introductions, and strategic partnerships to expand their market presence and capabilities. These activities drive innovation and growth within the human papillomavirus (HPV) vaccine market, ensuring continuous improvement and broadening service offerings.

Key Questions Answered in the Report

What are the key drivers of the human papillomavirus (HPV) vaccine market growth?

How are technological advancements influencing human papillomavirus (HPV) vaccine efficacy and safety?

What challenges are faced in the widespread adoption of human papillomavirus (HPV) vaccines?

What opportunities exist for human papillomavirus (HPV) vaccine market expansion in emerging markets?

How do government initiatives impact the human papillomavirus (HPV) vaccine market?

Which regions are expected to lead the human papillomavirus (HPV) vaccine market during the forecast period?

What are the trends in human papillomavirus (HPV) vaccination programmes?

How do public-private partnerships benefit the human papillomavirus (HPV) vaccine market?

What are the different types of human papillomavirus (HPV) vaccines available?

How do human papillomavirus (HPV) vaccines contribute to cancer prevention?

What role do hospitals and retail pharmacies play in the distribution of human papillomavirus (HPV) vaccines?

Which companies are leading the human papillomavirus (HPV) vaccine market, and what strategies are they employing?

Key Benefits for Stakeholders

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the human papillomavirus (HPV) vaccine market from 2017-2032.

The research report provides the latest information on the market drivers, challenges, and opportunities in the human papillomavirus (HPV) vaccine market.

The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.

Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyse the level of competition within the human papillomavirus (HPV) vaccine industry and its attractiveness.

The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Human Papillomavirus (HPV) Vaccine Market Overview: 8 Major Market
 - 3.1 Human Papillomavirus (HPV) Vaccine Market Historical Value (2017-2023)
 - 3.2 Human Papillomavirus (HPV) Vaccine Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 Human Papillomavirus (HPV): Disease Overview
 - 5.1 Guidelines and Stages
 - 5.2 Pathophysiology
 - 5.3 Screening and Diagnosis
 - 5.4 Therapy Pathway
- 6 Patient Profile
 - 6.1 Patient Profile Overview
 - 6.2 Patient Psychology and Emotional Impact Factors
 - 6.3 Risk Assessment and Therapy Success Rate
- 7 Human Papillomavirus (HPV) Vaccine Market Epidemiology Scenario and Forecast - 8 Major Markets
 - 7.1 8MM Epidemiology Scenario Overview (2017-2032)
 - 7.1.1 Prevalence, by Country

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Human Papillomavirus (HPV) Vaccine Market Landscape: 8 Major Market*
- 8.1 Human Papillomavirus (HPV) Vaccine Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Human Papillomavirus (HPV) Vaccine Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Indication
- 8.2.3 Analysis by Route of Administration
- 9 Human Papillomavirus (HPV) Vaccine Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Global Human Papillomavirus (HPV) Vaccine: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter's Five Forces Model
- 11.4.1 Bargaining Power of Suppliers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.2□Bargaining Power of Buyers
- 11.4.3□Threat of New Entrants
- 11.4.4□Threat of Substitutes
- 11.4.5□Degree of Rivalry
- 11.5□Key Demand Indicators
- 11.6□Key Price Indicators
- 11.7□Industry Events, Initiatives, and Trends
- 11.8□Value Chain Analysis
- 12□Human Papillomavirus (HPV) Vaccine Market Segmentation: 8 Major Markets
- 12.1□Human Papillomavirus (HPV) Vaccine Market by Type
- 12.1.1□Market Overview
- 12.1.2□Bivalent
- 12.1.3□Polyvalent
- 12.2□Human Papillomavirus (HPV) Vaccine Market by Indication
- 12.2.1□Market Overview
- 12.2.2□Genital Warts
- 12.2.3□HPV Associated Cancer
- 12.3□Human Papillomavirus (HPV) Vaccine Market by Route of Administration
- 12.3.1□Market Overview
- 12.3.2□Intravenous
- 12.3.3□Intramuscular
- 12.3.4□Others
- 12.4□Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
- 12.4.1□Market Overview
- 12.4.2□Hospital and Retail Pharmacies
- 12.4.3□Government Suppliers
- 12.4.4□Others
- 12.5□Human Papillomavirus (HPV) Vaccine Market by Region
- 12.5.1□Market Overview
- 12.5.2□United States
- 12.5.3□EU-4 and the United Kingdom
- 12.5.3.1□Germany
- 12.5.3.2□France
- 12.5.3.3□Italy
- 12.5.3.4□Spain
- 12.5.3.5□United Kingdom
- 12.5.4□Japan
- 12.5.5□India
- 13□United States Human Papillomavirus (HPV) Vaccine Market (2017-2032)
- 13.1□United States Human Papillomavirus (HPV) Vaccine Market Historical Value (2017-2023)
- 13.2□United States Human Papillomavirus (HPV) Vaccine Market Forecast Value (2024-2032)
- 13.3□United States Human Papillomavirus (HPV) Vaccine Market by Type
- 13.3.1□Market Overview
- 13.3.2□Bivalent
- 13.3.3□Polyvalent
- 13.4□United States Human Papillomavirus (HPV) Vaccine Market by Indication
- 13.4.1□Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.4.2 Genital Warts
- 13.4.3 HPV Associated Cancer
- 13.5 United States Human Papillomavirus (HPV) Vaccine Market by Route of Administration
 - 13.5.1 Market Overview
 - 13.5.2 Intravenous
 - 13.5.3 Intramuscular
 - 13.5.4 Others
- 13.6 United States Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
 - 13.6.1 Market Overview
 - 13.6.2 Hospital and Retail Pharmacies
 - 13.6.3 Government Suppliers
 - 13.6.4 Others
- 14 EU-4 and United Kingdom Human Papillomavirus (HPV) Vaccine Market (2017-2032)
 - 14.1 EU-4 and United Kingdom Human Papillomavirus (HPV) Vaccine Market Historical Value (2017-2023)
 - 14.2 EU-4 and United Kingdom Human Papillomavirus (HPV) Vaccine Market Forecast Value (2024-2032)
 - 14.3 EU-4 and United Kingdom Human Papillomavirus (HPV) Vaccine Market by Type
 - 14.3.1 Market Overview
 - 14.3.2 Bivalent
 - 14.3.3 Polyvalent
 - 14.4 EU-4 and United Kingdom Human Papillomavirus (HPV) Vaccine Market by Indication
 - 14.4.1 Market Overview
 - 14.4.2 Genital Warts
 - 14.4.3 HPV Associated Cancer
 - 14.5 EU-4 and United Kingdom Human Papillomavirus (HPV) Vaccine Market by Route of Administration
 - 14.5.1 Market Overview
 - 14.5.2 Intravenous
 - 14.5.3 Intramuscular
 - 14.5.4 Others
 - 14.6 EU-4 and United Kingdom Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
 - 14.6.1 Market Overview
 - 14.6.2 Hospital and Retail Pharmacies
 - 14.6.3 Government Suppliers
 - 14.6.4 Others
- 15 Japan Human Papillomavirus (HPV) Vaccine Market
 - 15.1 Japan Human Papillomavirus (HPV) Vaccine Market Historical Value (2017-2023)
 - 15.2 Japan Human Papillomavirus (HPV) Vaccine Market Forecast Value (2024-2032)
 - 15.3 Japan Human Papillomavirus (HPV) Vaccine Market by Type
 - 15.3.1 Market Overview
 - 15.3.2 Bivalent
 - 15.3.3 Polyvalent
 - 15.4 Japan Human Papillomavirus (HPV) Vaccine Market by Indication
 - 15.4.1 Market Overview
 - 15.4.2 Genital Warts
 - 15.4.3 HPV Associated Cancer
 - 15.5 Japan Human Papillomavirus (HPV) Vaccine Market by Route of Administration
 - 15.5.1 Market Overview
 - 15.5.2 Intravenous

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.5.3□Intramuscular
- 15.5.4□Others
- 15.6□Japan Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
- 15.6.1□Market Overview
- 15.6.2□Hospital and Retail Pharmacies
- 15.6.3□Government Suppliers
- 15.6.4□Others
- 16□India Human Papillomavirus (HPV) Vaccine Market
- 16.1□India Human Papillomavirus (HPV) Vaccine Market (2017-2032) Historical Value (2017-2023)
- 16.2□India Human Papillomavirus (HPV) Vaccine Market (2017-2032) Forecast Value (2024-2032)
- 16.3□India Human Papillomavirus (HPV) Vaccine Market by Type
- 16.3.1□Market Overview
- 16.3.2□Bivalent
- 16.3.3□Polyvalent
- 16.4□India Human Papillomavirus (HPV) Vaccine Market by Indication
- 16.4.1□Market Overview
- 16.4.2□Genital Warts
- 16.4.3□HPV Associated Cancer
- 16.5□India Human Papillomavirus (HPV) Vaccine Market by Route of Administration
- 16.5.1□Market Overview
- 16.5.2□Intravenous
- 16.5.3□Intramuscular
- 16.5.4□Others
- 16.6□India Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
- 16.6.1□Market Overview
- 16.6.2□Hospital and Retail Pharmacies
- 16.6.3□Government Suppliers
- 16.6.4□Others
- 17□Regulatory Framework
- 17.1□Regulatory Overview
- 17.2□US FDA
- 17.3□EU EMA
- 17.4□INDIA CDSCO
- 17.5□JAPAN PMDA
- 17.6□Others
- 18□Patent Analysis
- 18.1□ Analysis by Type of Patent
- 18.2□ Analysis by Publication Year
- 18.3□ Analysis by Issuing Authority
- 18.4□ Analysis by Patent Age
- 18.5□ Analysis by CPC Analysis
- 18.6□ Analysis by Patent Valuation
- 18.7□ Analysis by Key Players
- 19□Clinical Trial Analysis
- 19.1□Analysis by Trial Registration Year
- 19.2□Analysis by Trial Status
- 19.3□Analysis by Trial Phase

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.4□Analysis by Therapeutic Area
- 19.5□Analysis by Geography
- 20□Grant Analysis
- 20.1□Analysis by Year
- 20.2□Analysis by Amount Awarded
- 20.3□Analysis by Issuing Authority
- 20.4□Analysis by Grant Product
- 20.5□Analysis by Funding Institute
- 20.6□Analysis by Departments
- 20.7□Analysis by Recipient Organization
- 21□Strategic Initiatives
- 21.1□ Analysis by Partnership Instances
- 21.2□ Analysis by Type of Partnership
- 21.3□ Analysis by Leading Players
- 21.4□ Analysis by Geography
- 22□Supplier Landscape
- 22.1□Market Share by Top 5 Companies
- 22.2□Merck & Co., Inc .
- 22.2.1□Financial Analysis
- 22.2.2□Product Portfolio
- 22.2.3□Demographic Reach and Achievements
- 22.2.4□Company News and Developments
- 22.2.5□Certifications
- 22.3□GlaxoSmithKline plc .
- 22.3.1□Financial Analysis
- 22.3.2□Product Portfolio
- 22.3.3□Demographic Reach and Achievements
- 22.3.4□Company News and Developments
- 22.3.5□Certifications
- 22.4□Johnson & Johnson Services, Inc .
- 22.4.1□Financial Analysis
- 22.4.2□Product Portfolio
- 22.4.3□Demographic Reach and Achievements
- 22.4.4□Company News and Developments
- 22.4.5□Certifications
- 22.5□Serum Institute of India Pvt. Ltd .
- 22.5.1□Financial Analysis
- 22.5.2□Product Portfolio
- 22.5.3□Demographic Reach and Achievements
- 22.5.4□Company News and Developments
- 22.5.5□Certifications
- 22.6□ Bavarian Nordic A/S
- 22.6.1□Financial Analysis
- 22.6.2□Product Portfolio
- 22.6.3□Demographic Reach and Achievements
- 22.6.4□Company News and Developments
- 22.6.5□Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 22.7 Bharat Biotech International Limited (BBIL)
 - 22.7.1 Financial Analysis
 - 22.7.2 Product Portfolio
 - 22.7.3 Demographic Reach and Achievements
 - 22.7.4 Company News and Developments
 - 22.7.5 Certifications
- 22.8 Inovio Pharmaceuticals Inc .
 - 22.8.1 Financial Analysis
 - 22.8.2 Product Portfolio
 - 22.8.3 Demographic Reach and Achievements
 - 22.8.4 Company News and Developments
 - 22.8.5 Certifications
- 22.9 Sanofi SA
 - 22.9.1 Financial Analysis
 - 22.9.2 Product Portfolio
 - 22.9.3 Demographic Reach and Achievements
 - 22.9.4 Company News and Developments
 - 22.9.5 Certifications
- 22.10 Beijing Wantai Biolog Pha Ent Co Ltd
 - 22.10.1 Financial Analysis
 - 22.10.2 Product Portfolio
 - 22.10.3 Demographic Reach and Achievements
 - 22.10.4 Company News and Developments
 - 22.10.5 Certifications
- 22.11 Walvax Biotechnology Co., Ltd
 - 22.11.1 Financial Analysis
 - 22.11.2 Product Portfolio
 - 22.11.3 Demographic Reach and Achievements
 - 22.11.4 Company News and Developmentss
 - 22.11.5 Certifications
- 23 Human Papillomavirus (HPV) Vaccine Market - Distribution Model (Additional Insight)
 - 23.1 Overview
 - 23.2 Potential Distributors
 - 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Payment Methods (Additional Insight)
 - 25.1 Government Funded
 - 25.2 Private Insurance
 - 25.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Human Papillomavirus (HPV) Vaccine Market Report and Forecast 2024-2032

Market Report | 2024-09-30 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com